New Zealand

Home / Species & Products / Dairy Cattle / Orbenin Dry Cow

Orbenin Dry Cow

Orbenin Dry Cow is a specially prepared intramammary suspension for treatment of the dry cow.

Orbenin Dry Cow maintains effective antibiotic levels in the udder for a period of weeks and is non-irritant. Orbenin Dry Cow is bactericidal with activity against penicillin resistant and sensitive staphylococci, streptococci and Corynebacterium pyogenes.

Expand All
  • Approved uses/Indications

    The main purpose of dry cow antibacterial therapy is to treat subclinical mastitis at drying off. The use of routine dry cow therapy has been shown to achieve high levels of control of mastitis in the herd at calving. It eliminates almost all of the streptococcal infections and a majority of the staphylococcal infections caused by penicillin-resistant as well as sensitive organisms. Since the treatment is administered during the dry period there is no requirement to discard milk.

    Orbenin Dry Cow is active against Gram+ve organisms associated with mastitis. It is effective against Streptococcus agalactiae and other streptococcal species, penicillin-resistant and sensitive staphylococci and Corynebacterium pyogenes. Unlike natural penicillins it is not destroyed by staphylococcal penicillinase. It is therefore active against penicillin-resistant staphylococci, which are an important cause of mastitis.The benzathine salt of cloxacillin retains its activity over a prolonged period and, in the long-acting base, maintains effective antibacterial levels in the mammary glands of the dry cow for approximately 4 weeks. The antibiotic is bactericidal at the concentrations found in the udder after administration and therefore kills all the susceptible micro-organisms present at the time of dosing.

  • Packaging

    Orbenin Dry Cow is a stable suspension containing 500mg/syringe of cloxacillin as the benzathine salt in a long-acting base.

    Orbenin Dry Cow is available in buckets of 120 syringes.

  • Dosage & Administration

    Dry cow therapy should be used at drying off only. Treatment to be at least 30 days before calving. Orbenin Dry Cow must not be used for the treatment of the lactating cow. If a lactating cow is accidentally infused, milk must be withheld from the bulk supply for 30 days.

    Administer the contents of one syringe per quarter immediately after the final milking of a lactation. At the end of lactation, milk the cow out normally. Clean and disinfect the teat, infuse the contents of one syringe into each quarter and leave without milking out. Orbenin Dry Cow treatment can be followed by administration of TEATSEAL (ACVM A7294) to provide further protection from new intramammary infections. It is normally unnecessary and undesirable to introduce any further treatment during the dry period. Lactating cow products such as Orbenin L.A. (ACVM A3664) should be used if re-treatment is required during the dry period.

  • Precautions

    Penicillins may cause hypersensitivity (allergy) following inhalation, ingestion or skin contact. Do not handle this product if you know you are sensitised to, or if you have been advised not to work with, such preparations. Handle this product with great care to avoid exposure, taking all the recommended precautions, including the use of suitable protective clothing and gloves.

    Dry cow therapy should be used at drying off only. Treatment to be at least 30 days before calving. Since the period of activity of the formulation is prolonged, it is important that this preparation is not used for the occasional cow which may have a very short dry period of 30 days or less. This will avoid contamination of the milk after the colostrum has been removed. In such cases Orbenin L.A. (ACVM No. A3664) may be used at drying off. Lactating cow products should be used if re-treatment is required during the dry period.

    Orbenin Dry Cow must not be used for the treatment of the lactating cow. If a lactating cow is accidentally infused, milk must be withheld from the bulk supply for 30 days.

    Store below 25°C (air conditioning) in a cool, dry place.

    Withholding Periods:

    Milk: Milk for human consumption must not be taken from the first 8 milkings after calving. If calving occurs before 30 days after the last treatment, milk to be sold for human consumption may only be taken after the full 30 days from treatment and a further 8 milkings has elapsed. If a lactating cow is accidentally infused, milk must be withheld from the bulk supply for 30 days.

    Meat: Cows producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 28 days of the last treatment.

    Bobby calves:When a calf is given colostrum from a treated cow that has calved within the 30-day withholding period this calf must, subsequently, be fed milk that does not contain antibiotic residues and withheld from slaughter for 7 days.

  • Mandatories

    Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. ORBENIN is a registered trade mark of GlaxoSmithKline NZ Ltd. ACVM Registration No. A0888. RVM; Available only under Veterinary Authorisation.

    References:

    1. Smith, A; Westgarth, DR; Jones, MR; Neave, FK; Dodd, FH and Bander, GC. Veterinary Record (1967) 81:504-510
    2. Pankey, JW; Barker, RM; Twomey, A and Duirs, G. NZVJ (1982) 30:50-52
    3. Broadbanks, EO. NZVJ (1968) 16:83-84
    4. Brander, GC; Watkins, JH; and Gard, RP. Veterinary Record (1975) 97:300-304
    5. Ziv, G; Storper, M and Saran, A. The Veterinary Quarter (1981) 3:74-79
  • Contact Information

    For technical enquiries please phone Zoetis Technical Services on 0800 650 277.